New stent aims to keep multiple heart arteries open
NCT ID NCT06168305
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is tracking 1000 adults with multivessel coronary artery disease who received a special drug-coated stent called GENOSS® DES. The stent slowly releases sirolimus to help prevent the artery from narrowing again. Researchers are monitoring safety and effectiveness over time, including heart-related deaths, heart attacks, and the need for repeat procedures.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Sirolimus-eluting coronary stent (GENOSS® DES)
What this could lead to
If successful, this could confirm that the GENOSS® DES stent is a safe and effective option for people with blockages in multiple heart arteries.
What could go wrong
This is an observational study, not a randomized trial, so results may be less definitive. Stents carry risks like blood clots or re-narrowing, and long-term outcomes are still being tracked.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERCUTANEOUS CORONARY INTERVENTION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Korea University GURO Hospital
Seoul, Seoul, 08308, South Korea